Nantahala Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Nantahala Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$254K	–	133
2023 Q3	$254K	Sell	30,000 -64,939	-68%	-$618K	0.02%	118
2023 Q2	$902K	Sell	94,939 -3,335	-3%	-$30.6K	0.09%	93
2023 Q1	$541K	Sell	98,274 -5,041	-5%	-$33.6K	0.04%	104
2022 Q4	$839K	Sell	103,315 -3,286	-3%	-$29.9K	0.05%	90
2022 Q3	$981K	Sell	106,601 -6,499	-6%	-$67.9K	0.06%	89
2022 Q2	$1.29M	Sell	113,100 -4,216	-4%	-$67.3K	0.06%	91
2022 Q1	$2.49M	Sell	117,316 -9,387	-7%	-$212K	0.11%	80
2021 Q4	$3.67M	Buy	126,703 +114,851	+969%	+$5.81M	0.13%	87
2021 Q3	$1.16M	Sell	11,852 -648	-5%	-$70K	0.04%	115
2021 Q2	$1.63M	Hold	12,500	–	–	0.05%	108
2021 Q1	$2.26M	Buy	+12,500	New	+$2.41M	0.07%	97

Other funds holding ELTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nantahala Capital Management's ELTX Position: Q4 2023 in Review

Nantahala Capital Management sold out of Elicio Therapeutics (ELTX) in Q4 2023, closing a stake of 30,000 shares — an estimated $254K sold.

Nantahala Capital Management first reported a position in ELTX in Q1 2021 and held it in 11 quarters. The position peaked at $3.67M in Q4 2021. 18 funds tracked by Wall St. Rank hold ELTX as of Q4 2023.

Nantahala Capital Management reported no remaining Elicio Therapeutics position as of Q4 2023 after selling out during the quarter.
Nantahala Capital Management sold 30,000 Elicio Therapeutics shares in Q4 2023, an estimated $254K.
Nantahala Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and held it in 11 quarters.
Nantahala Capital Management's Elicio Therapeutics position peaked at $3.67M in Q4 2021.
18 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2023.

Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.